This retrospective analysis (n=431) of at-home ketamine treatments (1x p/w, 50-400mg lozenges) for depression, generalized anxiety, and social anxiety found statistically significant improvements in symptoms measured via PHQ-9, GAD-7, and SAD-D-10 at all follow-up time points (1-2-3 months). Minor side effects were reported by 18.8% of patients, resolving within 24 hours, and the majority concluded treatment within ≤ 6 months. No significant differences were observed between treatment-resistant and non-resistant depression outcomes.

Abstract of Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes

“Objective: To evaluate the effectiveness of repeated at-home ketamine treatments for depression, generalized anxiety, and social anxiety and assess safety in terms of adverse effects and tendency towards long-term use.

Methods: This retrospective analysis included patients with depression, generalized anxiety, and/or social anxiety who received ketamine treatment (delivered at-home via low-dose, sublingual lozenges) through a private telehealth provider. Data was collected between May 2022 and April 2023. The primary outcome was change in depression, generalized anxiety, and social anxiety symptoms from baseline to three follow-up time points, measured via Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder Assessment (GAD-7), and Social Anxiety Disorder Severity Scale (SAD-D-10), with analysis subgroups established based on baseline diagnosis. Secondary outcomes included side effects, adverse events, long-term use, well-being improvements, and comparison of outcomes between treatment-resistant and non-resistant depression cases.

Results: Of 431 patients (mean [SD] age, 43.6 [10.9] years; 49.2% women), 81 (18.8%) reported minor side effects resolving within 24 hours, and 397 concluded treatment in ≤ 6 months. Statistically significant improvement on the primary outcome was observed at all follow-ups in all three subgroups (p < 0.001). No significant differences were found between treatment-resistant and non-resistant depression outcomes.

Conclusions: Repeated sublingual ketamine significantly reduced depression, generalized anxiety, and social anxiety with no major adverse events and minimal tendency towards long-term use observed. These findings prompt further exploration of ketamine as an alternative or adjunct to medications such as SSRIs and benzodiazepines to minimize response delays and dependence risk.”

Authors: Lauren N. Swanson, Lila S. Jones, Jose Muñoz Aycart, Zhipeng Zhu, David M. Rabin & Taylor Kuhn

Summary of Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes

Introduction

Depressive and anxiety disorders are highly prevalent, debilitating conditions with considerable negative impacts on global disability and health-related quality of life. Despite their prevalence, treating them remains challenging, with SSRIs lacking widespread effectiveness and benzodiazepines having a range of undesirable side effects. Ketamine has been identified as a promising new treatment option for depression, but most research has focused on its use in more severe, treatment-resistant cases. It may also be useful for generalized anxiety disorder and social anxiety disorder.

Methods

To access this content, you must purchase one of the following memberships: Sprout Membership, Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes

https://doi.org/10.1101/2024.01.30.24301798

Open Access | Google Scholar | Backup | 🕊

Cite this paper (APA)

Swanson, L. N., Jones, L. S., Munoz Aycart, J., Zhu, Z., Rabin, D. M., & Kuhn, T. (2024). Sublingual Ketamine for Depression and Anxiety: A Retrospective Study of Real-World Clinical Outcomes. medRxiv, 2024-01.

Study details

Compounds studied
Ketamine

Topics studied
Depression Anxiety Treatment-Resistant Depression

Study characteristics
Observational Open-Label Longitudinal Within-Subject Randomized

Participants
431 Humans

Institutes

Institutes associated with this publication

Wonder Sciences
Wonder Sciences is a mental health and wellness ecosystem that pioneers innovative approaches to treatment and research.

Compound Details

The psychedelics given at which dose and how many times

Ketamine 50 - 400
mg | 1x